Cargando...
Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
Lefamulin is a novel pleuromutilin antibiotic with potent in vitro activity against key community-acquired bacterial pneumonia (CABP) pathogens. However, the clinical efficacy and safety of lefamulin for treating CABP remains unclear. An integrated analysis of 2 phase III trials investigating the cl...
Guardado en:
| Publicado en: | Medicine (Baltimore) |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wolters Kluwer Health
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7373590/ https://ncbi.nlm.nih.gov/pubmed/32702892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000021223 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|